Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Aslan's Varlitinib Fails to Meet Goals in Phase III Trial

publication date: Nov 13, 2019

Aslan Pharma of Singapore announced that its lead drug, varlitinib, did not meet its endpoints in a Phase III trial that enrolled patients with biliary tract cancer (BTC). Varlitinib, a small molecule pan-HER inhibitor, did not provide a significant improvement in progression free survival. The global trial enrolled 127 patients with biliary tract cancer who had failed first-line therapy. Aslan is analyzing a sub-group of the patients in which varlitinib did seem to provide a meaningful PFS improvement. More details....

Stock Symbol: (NSDQ: ASLN, TPEx: 6497)

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital